World Investment Advisors LLC Acquires New Position in OPKO Health, Inc. (NASDAQ:OPK)

World Investment Advisors LLC bought a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 40,717 shares of the biotechnology company’s stock, valued at approximately $61,000.

Other hedge funds also recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in OPKO Health during the third quarter worth $120,000. Barclays PLC raised its stake in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health during the 3rd quarter worth $45,000. XTX Topco Ltd boosted its position in shares of OPKO Health by 166.5% in the 3rd quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock worth $162,000 after buying an additional 67,883 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new stake in OPKO Health in the 3rd quarter valued at about $71,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Price Performance

OPKO Health stock opened at $1.57 on Friday. The firm’s 50-day moving average is $1.54 and its two-hundred day moving average is $1.48. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market capitalization of $1.07 billion, a P/E ratio of -8.26 and a beta of 1.62. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.76.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the purchase, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have bought 1,304,255 shares of company stock valued at $2,024,605. Company insiders own 47.26% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on OPK shares. Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.